Therapeutic Advances in Psychopharmacology (Nov 2024)
Plain Language Summary of Publication: A comparison of once-monthly and once-every-2-months injectable formulations of aripiprazole in people with schizophrenia
Abstract
The purpose of this summary is to explain key findings from a study that included people with schizophrenia, as described in two separate articles (see the ‘Further Information’ section for more details). The study compared a new formulation of aripiprazole, given as an injection once every 2 months, with a once‑monthly injection of aripiprazole.